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D92190 Influenceof RedWineandRedGrapeJuioaonLipidaandLipidPeroxidation
A.A. Schoanebarger, K. Schmidt, W. Maerz 1. KW3-/-fospit,/, 61462
Koenigstein, University Freibufg, Division of Clinical Chemist~, Department
of Medicine, Germany
A lower infarct rate with moderate alcohol consumption, especially with red
wine, has been shown in epidemiologic studies. Effects of alcohol on HDL-
Cholesterol and on lipid peroxidation have been postulated as mechanisms.
Therefore we examined the influence of moderate red wine consumption
(200 ml/day) on lipid metabolism and lipid peroxidation and the possible
influence of alcohol on a lipid lowering effect. After two weeks without con-
sumption of alcohol or grapes 24 healthy males (age 50 + 8 yeare) of normal
weight consumed in randomised fashion either 200 ml of red wine or 200
ml of red grape juice with their evening meals for 6 weeks. Blood samples
were taken on 2 consecutive days before and at the end of the 6 weeks.
Lipid peroxidation wasdeterminad by measuring the decrease of the content
of thiobarbituric acid reacting substances (TBARS) in response to copper
ions and the formation of conjugated dienes. Alcohol consumption was mea-
sured by self reporting and levels of carbohydrate deficient transferring(CDT).
Lipid levels were measured by standard laboratory tests. LDL-paroxidation
(TBARS and lag phase of diene formation) as well as the serum levels of
cholesterol (C), HDL-C, LDL-C, apolipoprotein (ape) Al, apo B, lipoprotein(a),
triglycerides, fibrinogen and platelets remained unchanged in troth groups.
Thromboplastin-time decreased from 92% to 65% (p = 0.004) in the red
wine group. The reporIed influence of high alcohol intake on lipid peroxida-
tion and HDL-C could not be found with moderate red wine consumption.
The mechanism of lower infarcts rates with moderate alcohol intake remains
unclear.
El92191 LDLSubclaasDistributionChangein FamilialCombinedHyperlipidemiaPatientsFollowing
GemflbrozilandNiacinTraatment
H.R. Superko, R.M. Krauss. Lawrence Berkeley National Laboratov,
University of California, Berkelex and Berkeley HeartLab, USA
Familial combined hyparlipidemia (FCH) is an inherited lipoprotein disorder
that is associated with increased CAD risk and a predominance of small,
dense LDL particles. The effects of gemfibrozil (G) and niacin (N) therapy
on LDL subclasses was investigated in 20 FCHL patients. After 6 wk of diet
stabilization, subjeots were randomized to placebo (P) or G (1,200 mg/d) for
12 wks and then niacin (1.500 m~d) was added to all subjects for 12 wks.
Lipoprotein mass concentrations were measured as a function of flotation
rate (Sf) in IDL (SI 12-20), large LDL (1,SI 7-12; H>Sf 5-7) and small LDL
(Ill, SI 3-5; IV, S~O-3). Changes in plasma lipid and lipoprotein levels from
baseline (mean + SD) for P and G groups (12 wks) were:
GrouP P (n = 10) G (n = 10) P VS.G (p)
Triglyceride –23 + 111 –189+ 97 0.001
HDL-Cholesterol 5+9 10* 12 0.23
LDL-Cholesterol 6 +27 –11 +27 0.15
IDL msss 1 &24 –29+20 0.002
LDL-I msss 11 l 22 16+58 0.82
LDL-11mass 16& 24 14+36 0,88
LDL-111mass –3 & 25 -32 +47 0.08
LDL4V maas -lo* 17 -16i17 0.38
With N + G, there was greater reduction in IDL (p = 0.06) and LDL41(p =
0.05) than with G alone.
Conclusion: Gemfibrozil therapy results in significant reductions in IDL
and small, dense LDL, but not LDL-C, in FCH. Addition of niacin results in
additional lipoprotein changes, including further reduction in IDL. Since IDL
levels are strongly related to angiographic progression of CAD, the results
suggest that G + N therapy maybe particularly effective in reducing CAD risk
in FCH.
1921-921 Cerivaatatin,aNewPotentHMG-CoAReductasa
Inhibitor:EfficacyandTolerabilityin Primary
Hypercholaaterolemia
W. Irwull 1, E. Steinz, E, Whalen, S. Ripa for the Cerivaatatin Study Group.
I Baylor-Methodist Lipid Research Clinic, Houaton, TX, USA, 2 Metabolic
and Atherosc/eroeis Research Centec Cincinnati, OH, USA
Cerivastatin (CER) is a novel, synthetic, potent, pure enantiomer and highly
selective HMG-COAreductase inhibitor, that effectively reduces cholesterol
levels at ultra-low dosea. We report a dose-ranging, randomized, doubla-
blind, placefm- (PLA) and positive-controlled multicentertrial for CER, in 939
patients with primaiy hypercholesterolemia. Patients received an AHA Step
1 diet for 10 weeks before randomization to either CER at doses of 0.05 mg,
0.1 mg, 0.2 mg or 0.3 mg, Iovastatin (LOV) 40 mg, or PLA; all once daily
for 24 weeks. LDL-cholesterol (C), total-C, HDL-C and triglycerides were
measured at every visit. Changes (% from baseline) in lipids at endpoint (up
to 24 weeks) were:
PLA CER CER CER CER LOV
0.05 mg 0.1 mg 0.2 mg 0,3 mg 40 mg
LDL-C +l.9– 13.5” –16.9* –25.6’ –28.5”
Total-C
–33.3*
+1,7 –9.6* –12.9* –17.6* –19,9’ –23.8*
*P <0.001 comparedto placebo
CER at all doses was well tolerated. There was no difference in the
numbers of patients discontinuing therapy due to adverse events (CER
3.7%, LOV 3.9%, or PLA 3.9%). LDL-C was reduced by approximately 6%
upon doubling the CER dose suggesting that the dose range tested is on the
steep portion of the dose-response curve. CER at ultra-low doses, all at least
100 times lower than LOV, is effective and well tolerated in reducing LDL-C
in patienta with primary hypercholesterolemia.
D92193 CanLisinoprilimproveendothelialfunctioninhyperlipidaemica?
A.F.C. Lee, J.B.C. Dick’, A.D. Struthers. Department of C/inica/
Pharmacology, University of Dundee, Dundee, DD19SX UK, 1Department
of Medicine, University of Dundee, Dundee. DD19SY UK
Endothelial function has been shown to be defective in hyperlipidaemic pa-
tients, and improvement can be demonstrated following dietary and drug
treatment. Animal studies have suggested that Angiotensin Converting En-
zyme (ACE) inhibitors may also improve endothelial functional. We aaaesaed
the effect of six months treatment with Iisinopril 20 mg/day on endothelial
function in a group of treated hyperlipidaemic patients. Methods: 40 patienta
were recruited. Baseline forearm venous occlusion piethysmography was
performed using acetylcholine (ACH) 7.5 @rein, 15 wg.rmin,30 wg/min, as
a endothelial dependent vasodilator, and sodium nitroprusside (NPR) 0.8
#g/ml, 1.6 ~g/ml and 3.2 #g/ml as an endothelial independent vaaodila-
tor. Subjects were randomised double blindly to receive either Lisinopril 20
mg/day (n = 20), or matched placebo (n = 20) for 6 months. After 6 months
treatment, plethsymography was repeated, using the same infusions. Ffe-
su/ts: Baseline variables (age, sex, blood pressure, weight, total chol) be-
tween groups were comparable. Cholesterol was unchanged. Active: Blood
pressure fell significantly, systolic 145 + 4 vs 129 + 4 (P < 0.0001), diastolic
83 + 2 vs 74 + 2 mmHg (P < 0.0001). An improvement was found in the
vasodilatory response (expressed as the ratio between the blood flow in the
infused arm against the control uninfused arm) to ACH (eg 4.45 + 0.48 vs
3.33 & 0.3 for ACH at 30 fi~min P < 0.03) and also for htPR (eg 3.88&
0.3 vs 3.0 + 0.2 at 3.2 wglmin P < 0.01). Placebo: ,Vasodiiatation deteri-
orated in response to ACH, with significance at one d08e only, but that to
NPR was unchanged. Conclusion.’The data presented are consistent with
Lisinopril having a beneficial effect on arterial function in hyperlipidaemic
patients.
D92194 TotalSerumCholesteroliathe beatPredictorforEndothelialDysfunctionin InternalMammary
ArterieeofCoronaryBypasaPatiente
A.A. Voors, M. Oosterga, H. Buikema, Y.M. Pinto, J.G. Grandjean,
W.J. Morehuis, J.H. Kingma, W.H. van Gilst. Universifyof Groningen & St.
Antonius Hospital Nieuwegein, the ~etherfands
To establish whether serum lipid levels could predict endothelial dysfunction
in internal mammary arteries (lMA’s) of coronary bypass patients, we mea-
suredfasting total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol
and apoB within 4 weeks prior to surgery. During surgery, segments of the
IMA’s were obtained a6 excess graft material, and mounted in organ baths.
Rings of these artery segments were contracted to 10 WM phenylephrine
(PE), followed by increasing doses of metacholine (ME) (10 nM-100 wM),
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an endothelial dependent vasodllator. Finally, 10 mM sodiumnitrite (an en-
dothelial independent vasodlliator) was added.
The patient group consisted of 37 patients, with a mean age of 61.4
(+ 8.4) years, 27% was female and the mean dilation to ME was 40% (*
24%) of the precontraotion to PE. Linear regreaaion showad that both total
sarum cholesterol (regression coefficient (r.c.)= 10.7%/mmol, p = 0.006) and
Idl-cholesterol (r.c.= 11.5%/mmol, p = 0.01) were predictors for impaired en-
dothelial dependent dilation. Adjusted for several other clinicel characteristics
in a multiple linear regression mcdel, total serum cholesterol was the only
statistically significant predictor of endothelial dysfunction (r.c 10.6%/mmol,
p = O.ooe). Endothelial independent vaaodilation to sodiumnitrite was not
influenced by serUmlipid levels.
Thesa results indicate that total cholesterol is tha best predictor for en-
dothelial dysfunction in IMA’s of coronary bypass patients.
D921 111 Plaque rupture in men is associated with high
serum cholesterol
A.P. Burke, A. Farb, Y. Liang, G. Malcom, J. Smialek, R. Virmani. Armed
ForcesInstituteof PathologyWashington,DC,USA,LouisianaState
Universi&NewOrfeans,USA
Tha asacciation between coronary plaqua rupture and risk factors has not
been fully explored. We prospectively examined 164 hearts from man dying
unexpectedly; th,era were 44 sudden coronaty deaths (SCD) with plaque
rupture (age 48 + 9), 53 SCD with stable plaque with or without healed
myocardial infarction (age 53+ 11),16SCDwitherod$d plaques (age46+9)
and 51 non-coronaty deaths (age 49 + 10year$). Heartsware perfusion fixed
at phyalologic pressures and coronay atteries seclioned serially. All areas
of cross sectional Iuminal narrowing z50Y0 were evaluated histologically for
thrombi. Postmortem sera were evaluated for % glycosylatad hemoglobin,
thiocyanate as an indicator for cigarette smoking, total cholesterol (TC), and
high density lipoprotein cholesterol (HDL-C). Mean TC/HDL was 8.5+ 0.6 in
SCD with plaque rupture, exceeding controls (5.0+ 0.3, p < 0.0001), SCD
with stable plaque (5.5 + 0.6, p < 0.0001), and SCD with eroded plaque
(5.0 + 1.9, p = 0.002). By logistic regression, TC/HDL-C was a predictor of
plaque rupture Independent of age, glycosylated hemoglobin, heart weight,
smoking history, and hypertension (p = 0.0008, odda ratio 5.1). These data
suggest that the reduced morbidity and mortality by cholesterol lowering in
primary and secondary prevention is related to the stabilization of plaques
with prevention of plaque rupture.
m921 112 Soluble Cell Adhesion Molecules Are Regulatedby Pleema Cholesterol in Familial
Hypercholesterolemis
T. Sampietro, M. Tuoni, M. Ferdeghini A. Ciarcfi i G. Sassi,
M. Fradiani1, c. Pronterat, A. Bbnda 1. cfW hrstjtuteOfc/injca/
physiologyPisa,Italy,1Irrstitutaofll MedicalClinic,Universityof Pisa,
Piea,Italy
How cholesterol (CH) lowering produces clinical benefits, besides the angio-
graphic evidences, it is unknown. In our study on the effects of low density
lipoproteins (LDL)-apheresis in patients with diet and drug reaistant familial
hypercholesterolemia (FH) weaddress$d the specific question if high plasma
CH Ievels’’perse” may adversely affect endothelium adhesiveness and if this
phenomenon might be reversible.
We studied, in 8 FH patients, the acute and after 2 and 6 days effect
of CH removal on plasma intercellular adesion molecule 1 (sICAM1) and
on endothelium leukocyte adhesion molecule 1 (sELAM1). Apolipoprotain
B containing lipoproteins were selectively absorbad on column of destran
sulfate celluloae and during 3.5-4 hours a plasma volume of 6.5-9.2 Iitres
was treated. CH, CH-LDL, apo B, TG and Lp(a), were reduced by 74%,
62%, 79%, 56%, 86%, respectively. No significant effect was observed on
HDL-CH. Clinical chemical and biocompatibilify showad minimal changes.
Basal sICAM1 and sELAMI levels were higher compared to healthy control
subjects; after, and not by, ldl-apheresis theywereconstantlY and significantly
(p <0.0091 and p <0.0004, respectively) reduced. Individual, pre and
poet treatment, valuea of both sICAM1 and sELAM1 were positively and
significantly (p <0.0001 and p <0.02, respectively) correlated with total CH.
Rebound sICAMI and sELAM1 curves showed a pattern similar to that of
total CH but not TG and Lp(a).
In the absence of changes of tumor necrosis factora and factors involved
in inflammation, these results indicate a possible role for CH in regulating
endothelium adhesiveness at least in FH and confirm, in a clinical setting,
the upregulation of endothelium adhesiveness observed in atherogenesis
induced in animal renderad hyperchole$terolemics.
\921-113~ lnflfJen~eofHYperllpidemlaOnR@st@nOsiSAfter
Coronary Artery Stent Implantation
A. Wehinger, H. Walter, E. Zitzmann, H.-J. Baum, S. Braun, M. Hadamitzky,
H. Schiihlen, S. Elezi, A. Schomig. DeutschesHerzzerrtrurnand/.
Medizin/soheKiln/k,Klhrikumrechtsderlsac TechnischeUniverslttft
Munich,Germany
Restenosis after percutaneouscoronaty angioplasty (PTCA) depends on var-
ious mechanisms such as intimal hyperplasia, elastic recoil, arterial remod-
eling and smooth muscle proliferation, wherass restenosis after stent im-
plantation is predominantly determined by neointimal proliferation. Hyperc-
holesterolemia is known to be a major risk factor for coronary artery disease,
but the association with neointimal proliferation has not been fully elucidated.
Therefore, the role of lipids on the development of restenosis after stent
placement has been investigated. We analyzed the association of serum
lipids with the development of restanosis (?50% diamater stanosis) of 750
lesions in 671 consecutive patients. They underwent successful stent implan-
tation between March 93 and March 96 and had repeat angiography after a
median of 191 days. For quantitative analysis an automated and computer
assisted edge detection method was used. Serum levels of total cholesterol,
LDL, HDL and Lp(a) were obtained at the time of the intervention and follow-
UPangiogram. There was no significant correlation of late lumen loss (mean:
1.1 + 0.03 mm) within the stantad segments or% restenosis (28.9%) and
the levels of total cholesterol, LDL, HDL and Lp(a), neither at the time of the
intervention nor at repeat angiogrephy.
k!2ul Reductiofl’Jf P’””m”’ipid’ero’i’es ’ur’ng’ow
Density Lipoprotein Immunapheresis
K.M.K@ner,s. Banyai, M. Jansen, G. Maurer, K. Derfler. UfIiVerSifyOf
Viknna,Austria
Extracorporal low density lipoprotein (LDL) elimination is frequently used
today for the treatment of drug-resistant hypercholesterolaemic patients.
One of the most specific apheresis methods, LDL-immunapheresla, was
daveloped to selectively remove LDL and lipoprotein (a) [Lp(a)] from plasma.
Since lipid peroxidation is one of the unwanted side effects of extracorporaal
plasma treatments, we followed the oxidative status of patiants treated with
LDL-immunapheresis. For this purpose lipid hydroperoxides, the primary
prcducts of lipid peroxidation and thiobarbituric acid-reacting substances
(TBARS), secondary products, were determined in 13 patients before, during
and after LDL-immunapheresis. The amount of plasma volume treated per
patient was 6164 + 546 ml. Treatment led to a reduction of total cholesterol
by89 +8%, of LDL-cholesterol by78.8 +7.3%, of HDL-cholesterol by 19.2 l
7.1% and of triglycerides by 37.6 + 21%. Apoiipoprotein-B, Lp(a) and apoAl
were reduced by 77.1 + 6.45%, 25 + 5.6% and 76.4 + 10.37., respectively.
Before treatment, mean plasma concentration of lipid hydroperoxides was
22.6 + 15.2 Kmol/L, whereas following treatment plasma hydroperoxides
were reduced to 6.9 + 7.4 Womol/L. This reduction of 64.7 & 27Y0 was
statistically highly significant (p < 0.001). Anon-significant change of TBARS
concentration from 0.30 + 0.26 Mmol/L to 0.23 + 0.13 wmol/L was also
obsarved. We conclude that LDL-immunapheresis is not only very effective
in reducing LDL- and Lp(a)-cholesterol, but also has a beneficial effect on
the oxidative status of the uatienta.
H AheringphysiCian BehaviorinLiPidTe@in9 and
Therapy: Results of a Houeestsff Education
Program
D.M. Lloyd-Jones, J,J. Lepore, G.S. Nagy, R.P. Giugliano, R.C. Pastemak.
MassachusettsGeneralHospital,Boston,MA, USA
Treatmentof hypercholesterolemiaforsecondary prevention ofoardiacevents
is now firmly established. Lipid levels remain valid for 24 hours after the onset
of myocerdial infarction (Ml) and 1994 national guideline recommend mea-
surement of serum lipids in patients (pts) within 24 hours in order to identify
those in need of therapy. We designed a housestaff education project to
alter physician behavior in obtaining lipid levels and treating elevated LDL-
cholesterol in pts with acute coronaw syndromes. The intervention consisted
of formal didactic sessions on lipid testing and twice-weekly reinforcement
sessiona on rounds by the medical chief resident, along with postad ra-
mindere in clinical areas. All pts with Ml during tha two month study period
(12/95-1/98) were identified by an alevated creatine kinase level and ela-
vatad MB fraction. Lipid testing and therapy rates were compared to a his-
torical control population (n= 280) admitted with acute coronav syndromes
over a previous recent 12 month period. Results:We identified 134 pte with
ML In pta for whom data was available, 35% had a history of hyperlipidemia,
of whom 469!. were on therapy at admission. SW5XVYPercent .of study Pts
compared to 45~oof controls (p = 0.0001) had lipid levels drawn at some
point during admission; 25%vs. 15% (p =0.03) had fasting panels by hospital
